Surrogate Endpoints Acceptable in AML Trials, Says FDA

The US Food and Drug Administration (FDA) has been harshly critized for using surrogate endpoints in clinical trials in its approval of new drugs, and especially so in oncology, where critics have argued that the only truly meaningful endpoint is overall survival (OS).